Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Revenue projections:

Revenue projections for DRREDDY
Revenue projections for DRREDDY

DRREDDY's revenue projections show a decrease from last year, which tends to make investors more cautious. This could have a negative impact on the company's bottom line, as lower revenues typically suggest reduced profitability and growth potential, prompting concern among investors.

Financial Ratios:

currentRatio 1.802000
forwardPE 20.928936
debtToEquity 20.328000
earningsGrowth -0.862000
revenueGrowth -0.116000
grossMargins 0.527680
operatingMargins 0.015420
trailingEps 51.450000
forwardEps 64.480100

With a current ratio 1.802, Dr. Reddy's Laboratories Limited demonstrates the ability to service its short-term debt without difficulty. The company's strong cash reserves and current assets ensure that it can meet its liabilities, reflecting financial stability and healthy liquidity.
DRREDDY's Forward PE is in an attractive range, meaning its stock price aligns well with earnings and isn't inflated. This creates room for growth, making it a solid investment opportunity for those looking to benefit from potential price appreciation.
DRREDDY's low Debt-to-Equity ratio shows the company avoids heavy reliance on debt. This balanced approach reduces financial risk, as it maintains a healthy equity position without excessive leverage, providing greater financial stability and flexibility.
DRREDDY's low earnings and revenue growth suggest that its profits could shrink. This points to a potential downturn in the company's financial outlook and may indicate challenges in maintaining profitability.
DRREDDY's negative gross and operating margins indicate that the company is operating at a loss. This reflects an inability to cover production costs and operational expenses, which could undermine its financial stability.
DRREDDY's forward EPS exceeding its trailing EPS means that the company is expected to increase profitability in the current financial year. This reflects improved earnings potential, signaling that DRREDDY is likely to outperform its previous year's financial performance.

Price projections:

Price projections for DRREDDY
Price projections for DRREDDY

DRREDDY's stock price has repeatedly hovered near the lower end of projections. This trend indicates that the company may be facing obstacles in achieving the growth anticipated by analysts.

Recommendation changes over time:

Recommendations trend for DRREDDY
Recommendations trend for DRREDDY


Recent analysis shows a strong buy bias for DRREDDY, encouraging investors to view it as a solid investment option. The positive sentiment surrounding DRREDDY suggests it could be an attractive place to allocate funds, motivating potential investors to consider the stock as a valuable part of their portfolio.